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ABSTRACT
A double-blind, double-dummy, multicentre, multinational, parallel-group study was designed to
establish proof of equivalence between oral gatiﬂoxacin and oral co-amoxiclav in the treatment of 462
patients with mild-to-moderate community-acquired pneumonia. Eligible patients were randomised
equally to either gatiﬂoxacin 400 mg once-daily plus matching placebo for 5–10 days, or amoxycillin
500 mg + clavulanic acid 125 mg three-times-daily for 5–10 days. The primary efﬁcacy endpoint was
clinical response (clinical cure plus improvement) at the end of treatment. Overall, a successful clinical
response was achieved in 86.8% of gatiﬂoxacin-treated patients, compared with 81.6% of those
receiving co-amoxiclav, while corresponding rates of bacteriological efﬁcacy (eradication plus presumed
eradication) were 83.1% and 78.7%, respectively. The safety and tolerability proﬁle of gatiﬂoxacin was
comparable to that of co-amoxiclav, with adverse gastrointestinal events, e.g., diarrhoea and nausea,
being the most common treatment-related adverse events in both groups. The study showed no
evidence of gatiﬂoxacin-induced phototoxicity, musculoskeletal disorders, or hepatic and renal
problems. Overall, this study showed that gatiﬂoxacin was equivalent clinically to a standard course
of co-amoxiclav in patients with community-acquired pneumonia, and that gatiﬂoxacin was safe and
well-tolerated.
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INTRODUCTION
Community-acquired pneumonia (CAP) is a sig-
niﬁcant cause of morbidity and mortality, especi-
ally among the elderly. In the USA alone, over
four million cases of CAP are diagnosed each
year, of which some 600 000 require hospitalisa-
tion [1]. With annual costs of about $23 billion, the
economic burden posed by this disease is consid-
erable [2].
Antimicrobial therapy plays a vital role in the
treatment of CAP, with studies showing that
prompt administration of antibiotic therapy can
have a signiﬁcant effect in reducing morbidity
and mortality associated with the disease [3].
There is a need to initiate antibiotic therapy early,
so treatment is usually empirical and coincident
with an initial clinical diagnosis of CAP. There-
fore, to be effective, ﬁrst-line antimicrobial agents
must provide adequate coverage of the pathogens
likely to be isolated from patients with CAP, and
should include both typical and atypical respir-
atory pathogens in their spectrum of activity.
While Streptococcus pneumoniae, Haemophilus inﬂu-
enzae and Moraxella catarrhalis are the most com-
mon pathogens isolated in patients with CAP,
atypical intracellular pathogens, such as Legionella
pneumophila, Mycoplasma pneumoniae and Chlamydia
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pneumoniae, are now being isolated with increas-
ing frequency [4–7].
Traditionally, patients with CAP have been
treated with oral penicillins, cephalosporins and
tetracyclines. Although these agents are still used
widely, the additional use of modern macrolides is
now recommended because of their activity
against atypical respiratory pathogens [8]. The
choice of ﬁrst-line antimicrobial treatment is
also complicated by the increasing prevalence of
resistant strains of respiratory pathogens, such as
penicillin-resistant pneumococci and b-lactamase-
producing strains ofH. inﬂuenzae andM. catarrhalis,
which render ineffective some of the traditional
antimicrobial agents, such as penicillins, cephalo-
sporins andmacrolides, used to treat patients with
CAP. The broad-spectrum ﬂuoroquinolones have
therefore been recommended for empirical therapy
of CAPbecause of their activity against bothGram-
positive and Gram-negative respiratory patho-
gens, including strains of penicillin-resistant
S. pneumoniae and b-lactamase-producing strains
of H. inﬂuenzae andM. catarrhalis [8–10].
Gatiﬂoxacin is an advanced-generation 8-meth-
oxyﬂuoroquinolone with a broad spectrum of
antibacterial activity which covers all the common
typical and atypical pathogens of CAP. Its superior
in-vitro activity, compared with many standard
agents, against common respiratory pathogens
[11–17] is accompanied by a favourable pharma-
cokinetic proﬁle, which includes excellent tissue
penetration and a long plasma half-life, enabling
once-daily dosing. Following oral dosing, high and
sustained concentrations of gatiﬂoxacin are
achieved in the respiratory tract that are above
the MICs for most infecting pathogens encoun-
tered in CAP [18]. High drug concentrations at the
site of infection are considered essential for effect-
ive eradication of bacteria from the lungs [19].
The primary objective of the present study was
to determine the efﬁcacy and safety in adult
patients with CAP of a once-daily oral dose of
gatiﬂoxacin 400 mg in comparison with three-
times-daily oral co-amoxiclav (amoxycillin
500 mg + clavulanic acid 125 mg).
PATIENTS AND METHODS
Study design and number of patients
This was a randomised, double-blind, double-dummy, multi-
centre, multinational, parallel-group study, designed to com-
pare the efﬁcacy and safety of oral gatiﬂoxacin with oral
co-amoxiclav in the treatment of over 400 patients with typical
CAP. The protocol complied with the Guidelines for the
Clinical Evaluation of Anti-infective Products [20]. Written
informed consent was obtained from all patients before the
start of the study, which was approved by the appropriate
Ethics Committee in each country and conducted in accord-
ance with the current Declaration of Helsinki.
Patients
Adult (aged ‡ 18 years) ambulatory or hospitalised male and
female patients with a primary diagnosis of CAP of mild-to-
moderate intensity were eligible for enrolment. The diagnosis
required evidence of new and persistent inﬁltrates on chest
X-ray, indicative of bacterial pneumonia, within 48 h of the
start of therapy, as well as signs and symptoms of pneumonia,
such as cough, dyspnoea, chills, sputum production and chest
pain. Other inclusion criteria included evidence of fever
> 38 C, or a white blood cell count of > 10 000 ⁄mm3, or
microbiological evidence of bacterial pneumonia. Pregnant
and nursing mothers were excluded from the study, but
female patients of childbearing age could be included if they
had a negative pregnancy test and used reliable contraception
throughout the study period.
Patients were excluded if they were receiving current
antibiotic therapy for other infectious diseases, had extratho-
racic symptoms, needed additional antibiotic or intravenous
treatment for pneumonia or antibiotic therapy for > 10 days,
had concomitant pulmonary or respiratory tract disease, or
had pneumonia requiring ventilation. Other exclusion criteria
included intolerance or hypersensitivity to quinolone or
b-lactam antibiotics, the need for immunosuppressive therapy,
or participation in another study within the previous 4 weeks
or in a current parallel study. Severe hepatic, renal or coronary
dysfunction, HIV infection, epilepsy, severe allergic or haem-
atological disease, severe dehydration or blood donation
(> 500 mL) within the previous 3 months, were also criteria
for exclusion. Patients with a history of psychiatric illness or
suicide risk within the previous 2 years, a history of alcohol,
substance or drug abuse, or any condition likely to affect the
disposition of study medication, were also excluded.
Diagnostic procedures
Respiratory secretions for Gram’s stain, culture and suscepti-
bility testing were obtained from spontaneously expectorated
sputum, or by transtracheal or endotracheal aspiration,
bronchoscopic procedures or lung biopsy. These tests were
carried out within 48 h before the start of treatment, on days
4–6 during treatment, 1–3 days after the end of treatment, and
14–28 days post-treatment. Two venous blood samples were
also cultured for aerobes and anaerobes at study admission,
and this was repeated at subsequent visits if the admission
blood culture was positive or if indicated clinically. Culture
was only done if purulent respiratory secretions contained > 25
polymorphonuclear leukocytes and < 10 squamous epithelial
cells ⁄ low-power (· 100) magniﬁcation ﬁeld. Susceptibility of
cultured pathogens to gatiﬂoxacin and co-amoxiclav was
determined by the disk diffusion method.
Diagnosis of pneumonia associated with atypical respirat-
ory pathogens was based on serological tests for C. pneumoniae,
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Chlamydia psittaci, Coxiella burnettii, M. pneumoniae and
L. pneumophila, in which a four-fold rise in antibody titre in
paired sera taken 14–28 days apart was considered a current
deﬁnite infection. Single high titres against atypical pathogens
were considered to be indicative only of possible infection.
Study medication
Patients were assigned randomly to one of two treatment
groups, in a ratio of 1:1, in which they received either a once-
daily oral dose of gatiﬂoxacin 400 mg plus matching placebo
for 5–10 days, or oral amoxycillin 500 mg + clavulanic acid
125 mg three-times-daily for 5–10 days.
Clinical efﬁcacy assessment
Before administration of the study drugs, all patients gave a
detailed medical history and underwent a complete physical
examination for clinical signs and symptoms of pneumonia,
together with an assessment of vital signs, a chest X-ray and
laboratory analyses. Repeated physical examinations, together
with an assessment of vital signs, as well as clinical signs and
symptoms of pneumonia, were carried out during treatment
(days 4–6), at the end of treatment (days 1–3 post-treatment),
and at the end of the study (14–28 days post-treatment). Chest
X-rays were performed at the end of treatment and, if clinically
indicated or not done at previous visits, at the end of the study.
Clinical response (clinical cure plus improvement) at the
end of treatment was the primary efﬁcacy endpoint in this
study. Clinical cure was deﬁned as a complete resolution of
acute signs and symptoms of pneumonia, together with
improvement or lack of progression of imaging, and no reason
for clinical failure. Clinical improvement was deﬁned as
resolution of > 50% of all signs and symptoms of pneumonia,
together with improvement or lack of progression of imaging,
resolution of fever if elevated at enrolment, and no reason for
clinical failure. Clinical failure was deﬁned as persistence or
progression of all signs and symptoms of pneumonia after
3–5 days of treatment, a lack of improvement in any signs and
symptoms of pneumonia and in chest X-ray at the end of
treatment, or a lack of resolution of > 50% of signs and
symptoms of pneumonia. Additional reasons for clinical
failure included fever at follow-up or end of the study,
progression of pneumonia-related radiographical abnormalit-
ies, development of an active infection, a change in or use of
additional antibiotics, withdrawal because of treatment-related
adverse events, or death caused by pneumonia.
Analyses were based primarily on the modiﬁed intent-to-
treat population (mITT), which included all patients who had
received at least one dose of study medication and had the
study disease. Analyses were also carried out on the efﬁcacy
analysable population (EAP), a subset of the mITT population.
This comprised patients who had completed 72 h of treatment,
had complied fully with the dosing regimen, were assessed
within the speciﬁc time windows required by the study
protocol, did not develop concurrent illnesses likely to inter-
fere with treatment effectiveness, and had received no other
antibiotics except for topical agents.
Bacteriological efﬁcacy assessment
Bacteriological response at the end of treatment and the end of
the study was a secondary efﬁcacy endpoint. Patients were
considered to have responded to treatment if eradication or
presumed eradication of the causative organism was achieved,
with or without colonisation. Eradication was deﬁned as
elimination of the original causative organism(s) from the
same site; presumed eradication was deﬁned as the absence of
appropriate material for culture because the patient had
improved clinically and did not produce sputum, or because
repeated aspiration of pleural ﬂuid was clinically unjustiﬁed.
Colonisation was deﬁned as the development of a positive
sputum culture, with a bacterial strain other than the primary
causative organism, that appeared > 48 h after initiation of
therapy and persisted in at least two repeated cultures in the
absence of fever, leukocytosis, persistence or progression of
pneumonia, or evidence of infection at a distant site.
Bacteriological responsewas considered unsatisfactory if the
outcome was persistence, presumed persistence, relapse, su-
perinfection or reinfection. Persistence was deﬁned as a failure
to eradicate the causative organism from the site of infection,
irrespective of the presence or absence of signs of infection.
Presumed persistence was deﬁned as a failure in the absence of
material for culture, or change of therapy because of inadequate
efﬁcacy, or discontinuation because of inadequate efﬁcacy.
Relapse was deﬁned as initial eradication of the original
pathogen isolated at baseline, followed by reinfection with the
same pathogen at the end of the study. Superinfection was
deﬁned as the development of a new lower respiratory tract
infection caused by a newor resistant pathogen not identiﬁed as
the original causative organism. Reinfection was deﬁned as
infection with a new pathogen at the end of the study.
Safety assessment
All patients who received at least one dose of study medication
were included in the safety analyses. These were based on the
incidence and severity of all adverse events and their rela-
tionship to study medication, as well as changes from baseline
in vital signs and clinical chemistry, haematology and urin-
alysis parameters.
Statistical analyses
The sample size of 456 patients assumed that the probability of
a successful clinical response (primary efﬁcacy endpoint) was
80% for both treatments, and that the maximal acceptable
difference was 15% with a type II error probability of 20%.
Allowance was also made for 15% dropout and an assumption
that 33% of patients would have bacteriological conﬁrmation
of CAP.
Demographic and baseline data for the two treatment
groups were compared by the Cochran–Mantel–Haenszel test
with adjustment for centre, or the F-test adjusting for centre,
and centre-by-treatment, as appropriate. A two-sided 95%
conﬁdence interval (CI) for the difference in clinical response
to oral gatiﬂoxacin and co-amoxiclav was calculated, in which
the procedure described by Farrington and Manning was used
to compute the CIs [21]. For equivalence to be shown, the
lower bound of the two-sided 95% CIs for the observed
difference between treatments must not exceed ) 15%. Clinical
cure rates in each group were summarised, with 95% CI
calculated according to the Pearson and Clopper method [22].
Bacteriological response was compared by analysing the
patient and pathogen response to treatment in patients with
bacteriological conﬁrmation at admission. The absolute and
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relative frequencies for bacteriological response and the 95%
CI for patient response rate within treatment was calculated, as
well as the 95% CI for the difference in patient response rates
to treatments. The same statistical procedures were applied to
other secondary endpoints, such as clinical response at the end
of the study and clinical cure rate at the end of treatment and
study, while the remaining secondary endpoints, which
included treatment duration and chest X-ray ﬁndings, were
compared using descriptive statistics.
RESULTS
Patient population
In total, 462 patients from 73 centres in 16
countries, most of which were in Europe, were
randomised to treatment, of whom 228 received
gatiﬂoxacin 400 mgand234 receivedco-amoxiclav.
The two treatment groups were comparable with
respect to baseline demographic characteristics
and respiratory status such as underlying chronic
obstructive pulmonary disease and smoking
history (Table 1). Of these, 456 patients were inclu-
ded in the primary mITT (228 each in the gatiﬂ-
oxacin and co-amoxiclavgroups). Six patientswere
excluded from the co-amoxiclav group because
they did not have the disease being studied.
Baseline microbiology
As is usual in community-based clinical trials,
most bacteriological samples at admission were
from sputum cultures (92% in the gatiﬂoxacin
group vs. 95% in the co-amoxiclav group,
while 0.7% vs. 0.9% were from transtracheal
aspiration, 2.9% vs. 0.9% from endotracheal
aspiration, and 4.3% vs. 3.6% were bronchoalve-
olar lavage samples).
The most common pathogens isolated at base-
line were consistent with a diagnosis of CAP, and
were mainly isolates of S. pneumoniae (n ¼ 61) and
H. inﬂuenzae (n ¼ 48) (Table 2). Seven patients in
the gatiﬂoxacin group and ﬁve in the co-amoxi-
clav group had positive blood cultures. In the
gatiﬂoxacin group, S. pneumoniae was isolated in
ﬁve cases and Staphylococcus aureus in two cases,
while in the co-amoxiclav group, S. pneumoniae,
Staph. aureus and Klebsiella pneumoniae were isola-
ted in three cases, one case and one case, respect-
ively. Pneumonia caused by atypical pathogens
(M. pneumoniae, L. pneumophila, C. psittaci) was
diagnosed deﬁnitively in only 35 patients
(19 gatiﬂoxacin group; 16 co-amoxiclav group),
while 36 patients had a possible diagnosis of
pneumonia caused by atypical pathogens, as
deﬁned by a single high-titre antibody result.
With regard to patients with chronic obstruct-
ive pulmonary disease, 12 of the 18 patients in the
gatiﬂoxacin group and six of the 16 in the
co-amoxiclav group had no pathogen at admis-
sion. The remaining six patients in the gatiﬂoxacin
group yielded an isolate of S. pneumoniae (n ¼ 3),
H. inﬂuenzae (n ¼ 3) or K. pneumoniae (n ¼ 1),
while patients in the co-amoxiclav group yielded
four S. pneumoniae isolates, two H. inﬂuenzae
isolates, and one isolate each of Haemophilus







Male 148 (64.9%) 141 (60.3%)
Female 80 (35.1%) 93 (39.7%)
Race
Caucasian 171 (75.0%) 175 (74.8%)
Black 52 (22.8%) 53 (22.7%)
Asian 1 (< 1.0%) 2 (< 1%)
Other 4 (1.8%) 4 (1.7%)
Mean age in years (SD) (range) 49.2 (16.70) (18–89) 50.2 (17.28) (18–88)
Mean weight in kg (SD) (range) 70.5 (15.45) (38–129) 70.2 (14.38) (36–125)
Smoking history
Never smoked 93 (41.0%) 91 (39.1%)
Current smoker 88 (38.8%) 80 (34.3%)
Ex-smoker 46 (20.3%) 62 (26.6%)
Missing 1 1
History of COPD 18 (7.9%) 16 (6.8%)
Alcohol consumption
Not done 0 1
None 95 (41.7%) 110 (47.0%)
Rarely 92 (40.4%) 89 (38.0%)
Often 33 (14.5%) 24 (10.3%)
Daily 8 (3.5%) 10 (4.3%)
COPD, chronic obstructive pulmonary disease.






Patients with pathogen 75 84
Single pathogen 61 (26.8%) 68 (29.8%)
Multiple pathogens 14 (6.1%) 16 (7.0%)
Causative pathogens 90 (100%) 104 (100%)
Gram-positive organisms
Streptocoocus pneumoniae 28 (31.1%) 33 (31.7%)
Penicillin-susceptible 19 (21.1%) 17 (16.3%)
Penicillin-intermediate 2 (2.2%) 3 (2.9%)
Penicillin susceptibility unknown 7 (7.8%) 13 (12.5%)
Staphylococcus aureus 7 (7.8%) 6 (5.8%)
Streptococcus viridans group 4 (4.4%) 4 (3.8%)
Streptococcus pyogenes 4 (4.4%) 3 (2.9%)
Gram-negative organisms
Haemophilus inﬂuenzae 26 (28.9%) 22 (21.2%)
Moraxella catarrhalis 3 (3.3%) 10 (9.6%)
Haemophilus parainﬂuenzae 3 (3.3%) 3 (2.9%)
Non-fermenting bacteria
Pseudomonas aeruginosa 3 (3.3%) 1 (< 1.0%)
Enterobacteriaceae
Klebsiella pneumoniae 2 (2.2%) 4 (3.8%)
Escherichia coli 4 (4.4%) 1 (< 1.0%)
Other enteric bacteria 0 13 (12.5%)
Lode et al. Gatiﬂoxacin vs. co-amoxiclav in CAP 515
 2004 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 10, 512–520
parainﬂuenzae, Pseudomonas aeruginosa, Pseudomon-
as ﬂuorescens, M. catarrhalis and K. pneumoniae.
Clinical outcome
Within the limits of treatment duration of
5–10 days, 9% of gatiﬂoxacin-treated patients and
11% of co-amoxiclav-treated patients received
< 7 days of treatment; 89% and 85%, respectively,
received treatment for 7–10 days; and 2% and 4%,
respectively, received treatment for > 10 days.
Overall, the average therapy duration of 9 days
was the same in the two treatment groups.
At the end of treatment, a successful clinical
response was achieved in 86.8% of gatiﬂoxacin-
treated patients, compared with 81.6% of those
receiving co-amoxiclav. The two-sided 95% CI for
the difference between the two treatments was
well within the speciﬁed limit, indicating clinical
equivalence for the two treatments (Table 3).
These results were mirrored by those of the EAP,
in which clinical response at the end of treatment
for gatiﬂoxacin and co-amoxiclav was 89.6%
(190 ⁄ 212) and 84.8% (173 ⁄ 204), respectively.
Equivalence was also demonstrated for secon-
dary clinical endpoints, although there was a trend
towards higher rates of clinical cure with gatiﬂ-
oxacin at both the end of treatment and at the end
of the study, which was also seen in the primary
endpoint analysis (Table 3). Of the small number
of patients with a deﬁnitive diagnosis of pneu-
monia caused by atypical pathogens (M. pneumo-
niae, L. pneumophila, Chlamydia spp.), all but one of
those who received gatiﬂoxacin were treated
successfully at both the end of treatment and at
the end of the study. The one case classiﬁed as a
clinical failure at the end of treatment, because of
continuing clinical signs and symptoms, resolved
by the end of the studywithout further therapeutic
measures. In contrast, only 12 of the 16
co-amoxiclav-treated patients had a successful
clinical outcome at the end of treatment, and only
11 out of 16 at the end of the study.
Clinical failure occurred with 30 (13.2%) and
42 (18.4%) of cases in the gatiﬂoxacin and
co-amoxiclav treatment groups, respectively. Clin-
ical failure was caused primarily by the need for
additional or new antibiotics for pneumonia (nine
gatiﬂoxacin vs. 19 co-amoxiclav patients), as well
as incomplete resolution of symptoms (11 gatiﬂ-
oxacin vs. six co-amoxiclav patients), premature
withdrawal because of treatment-related adverse
events (ﬁve patients in each group), complete
lack of improvement (one gatiﬂoxacin vs. three
co-amoxiclav patients), and progression of radio-
graphical abnormalities (two gatiﬂoxacin vs. one
co-amoxiclav patient).
In the mITT population, clinical success was
accompanied by a marked improvement in clin-
ical symptoms, and evidence of resolution of
infection on chest X-ray, in both treatment groups
at the end of treatment and at the end of the
study.
Bacteriological outcome
Within the mITT population, the bacteriological
outcome was evaluated for 65 patients treated
with gatiﬂoxacin and 75 with co-amoxiclav.
Treatment was successful in 54 (83.1%) and 59
(78.7%) patients at the end of treatment, respect-
ively. Corresponding rates at the end of the study
were 78.7% and 75.0%, respectively. The two-
sided 95% CI for the difference between the two
treatments at the end of treatment () 9.29%;
18.11%) and at the end of the study () 11.36%;
18.74%) indicated equivalent bacteriological efﬁc-
acy for the two antibiotic regimens. The favour-
able bacteriological results for gatiﬂoxacin in the
mITT population were similar in the EAP, with
bacteriological response at the end of treatment in
50 (84.7%) and 54 (80.6%) patients, respectively.
Overall, there was no bacteriological response in
11 (16.9%) and 16 (21.3%) patients, respectively,
which, in most cases (ten vs. 15), was caused
by persistence or presumed persistence of
infection.
Table 3. Assessment of clinical response to treatment with
gatiﬂoxacin or co-amoxiclav at end of treatment and end of
study in the mITT population
Outcome Gatiﬂoxacin Co-amoxiclav
End of treatmenta n ¼ 228 n ¼ 228
Clinical response
(cure + improvement)
198 (86.8%) 186 (81.6%)
Clinical cure 123 (53.9%) 108 (47.4%)
Clinical improvement 75 (32.9%) 78 (34.2%)
Clinical non-response
(failure + indeterminate)
30 (13.2%) 42 (18.4%)
End of studyb n ¼ 211 n ¼ 211
Clinical response
(cure + improvement)
184 (87.2%) 166 (78.7%)
Clinical cure 141 (66.8%) 133 (63.0%)
Clinical improvement 43 (20.4%) 33 (15.6%)
Clinical non-response
(failure + indeterminate)
27 (12.8%) 45 (21.3%)
a95% conﬁdence intervals: gatiﬂoxacin 400 mg vs. co-amoxiclav () 1.80%; 12.33%).
b95% conﬁdence intervals: gatiﬂoxacin 400 mg vs. co-amoxiclav (0.98%; 16.09%).
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For bacteriologically evaluable patients in
the mITT population, gatiﬂoxacin successfully
eradicated 91.7% of S. pneumoniae at the end of
treatment compared with 100% with co-amoxi-
clav, a difference that was not statistically signiﬁ-
cant. Activity was also similar against strains of
H. inﬂuenzae, M. catarrhalis and Staph. aureus
(Table 4).
Clinical and bacteriological outcome for patients
with bacteraemia
Of the seven patients in the gatiﬂoxacin group
who had positive blood cultures, six responded to
gatiﬂoxacin therapy. This included four cases of
S. pneumoniae and two cases of Staph. aureus
bacteraemia. One patient with a gatiﬂoxacin-
susceptible S. pneumoniae blood isolate was
considered as a clinical failure because of discon-
tinuation of therapy caused by nausea and
stomachache on the second day of treatment after
two doses of gatiﬂoxacin. Notably, this patient
had a history of duodenal ulcer.
In the co-amoxiclav group, four of ﬁve patients
with bacteraemia responded to treatment. One
case with concomitant Staph. aureus bacteraemia
needed a change in antibiotic therapy after 2 days
and was thus considered a clinical failure.
Safety
Overall, both antibiotics were well-tolerated by
patients in this study, with the adverse event
proﬁle being similar for gatiﬂoxacin and
co-amoxiclav. From the start of dosing to the end
of treatment, gastrointestinal disturbances were
the most common treatment-related adverse
events, although only diarrhoea occurred with a
frequency of > 5% in both groups (Table 5). Most
adverse eventsweremild-to-moderate in intensity.
Serious adverse events occurred with similar fre-
quency in the two groups, affecting 17 (7.4%)
gatiﬂoxacin-treated patients and 16 (6.8%) of those
treated with co-amoxiclav, but in only one patient
in each group was this attributed to study medi-
cation. Additional safety assessments (of special
relevance to the ﬂuoroquinolones) showed no
evidence of phototoxicity, cardiotoxicity, adverse
effects on the musculoskeletal system, or renal or
hepatic toxicity, in either treatment group. There
were also no treatment-related cases of crystalluria.
Premature discontinuation because of adverse
events occurred in ten (4.4%) and 11 (4.7%)
patients in the gatiﬂoxacin and co-amoxiclav
groups, respectively; in eight cases, the adverse
events were considered to be serious. Three
patients in each treatment group died within
30 days of the last dose of study medication. Five
of these deaths were unrelated to study medica-
tion, while the sixth, a death in the co-amoxiclav
group, was caused by hepatic failure. Overall, no
clinically meaningful changes from baseline were
observed in relation to clinical chemistry, haema-
tology and urinalysis parameters. Changes in
vital signs were consistent with improvement in
disease state.
DISCUSSION
The results of this study demonstrate that once-
daily gatiﬂoxacin 400 mg is clinically and
Table 4. Assessment of bacteriological response to treat-
ment with gatiﬂoxacin or co-amoxiclav at end of treatment






Total pathogens 90 104
All pathogens
End of treatment 67 ⁄ 78 (85.9%) 78 ⁄ 94 (83%)
End of study 59 ⁄ 72 (81.9%) 64 ⁄ 80 (80%)
Streptococcus pneumoniae
End of treatment 22 ⁄ 24 (91.7%) 30 ⁄ 30 (100%)
End of study 18 ⁄ 23 (78.3%) 19 ⁄ 21 (90.5%)
Haemophilus inﬂuenzae
End of treatment 21 ⁄ 22 (95.5%) 16 ⁄ 19 (84.2%)
End of study 18 ⁄ 20 (90%) 14 ⁄ 18 (77.8%)
Moraxella catarrhalis
End of treatment 2 ⁄ 2 (100%) 9 ⁄ 10 (90%)
End of study 2 ⁄ 2 (100%) 7 ⁄ 8 (87.5%)
Staphylococcus aureus
End of treatment 7 ⁄ 7 (100%) 3 ⁄ 5 (60%)
End of study 7 ⁄ 7 (100%) 3 ⁄ 5 (60%)
Haemophilus parainﬂuenzae
End of treatment 3 ⁄ 3 (100%) 2 ⁄ 2 (100%)
End of study 3 ⁄ 3 (100%) 3 ⁄ 3 (100%)
Table 5. Summary of the most frequent (‡ 1% patients in
either group) treatment-related adverse events following
administration of gatiﬂoxacin or co-amoxiclav (from start
to end of treatment)
No. (%) of patients experiencing





Diarrhoea 13 (5.7%) 16 (6.8%)
Nausea 10 (4.4%) 6 (2.6%)
Thrush 6 (2.6%) 3 (1.3%)
Vomiting 4 (1.8%) 4 (1.7%)
Abdominal pain 4 (1.8%) 1 (< 1%)
Abnormal hepatic function 2 (< 1.0%) 3 (1.3%)
Increased serum alkaline phosphatase 3 (1.3%) 1 (< 1.0%)
Leukopenia 2 (< 1.0%) 3 (1.3%)
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bacteriologically equivalent to a standard course
of three-times-daily co-amoxiclav in the treatment
of CAP. The study population consisted of
patients with mild-to-moderate bacterial CAP, in
whom the infecting pathogens are most com-
monly S. pneumoniae, H. inﬂuenzae and M. catarrh-
alis and, to a lesser extent, Staph. aureus,
K. pneumoniae and other Enterobacteriaceae [23].
Consistent with the bacterial aetiology of the
disease, the pathogens isolated most frequently
from patients at admission were, in order of
frequency, S. pneumoniae, H. inﬂuenzae, M. catarrh-
alis and Staph. aureus. Relatively few patients in
this study were infected with atypical respiratory
pathogens.
Both study drugs achieved high and sustained
clinical response rates that were, in general,
accompanied by a decrease in signs and symp-
toms of pneumonia, together with improved
radiographical ﬁndings. The antibacterial activity
of gatiﬂoxacin against the main typical respirat-
ory pathogens was conﬁrmed by the bacteriologi-
cal outcome, which correlated closely with clinical
ﬁndings, and was comparable to eradication rates
achieved with other broad-spectrum ﬂuoroquino-
lones [23–27]. Against S. pneumoniae, including
strains of intermediate penicillin susceptibility,
gatiﬂoxacin eradicated > 90% of isolates success-
fully.
The results of the present study are consistent
with those of other studies in which gatiﬂoxacin
has been used to treat patients with CAP, where
clinical cure rates of > 95% have been reported
[28–31]. This includes patients infected with
multiresistant strains of S. pneumoniae, H. inﬂuen-
zae and M. catarrhalis, the presence of which can
jeopardise treatment outcome seriously if older
standard antimicrobial agents, such as penicillins,
cephaloporins and macrolides, are used as ﬁrst-
line agents for empirical therapy of CAP.
In the present study, high rates of clinical and
bacteriological efﬁcacy were accompanied by
good drug safety and tolerability, with the fre-
quency and nature of adverse events being similar
in the two treatment groups. Concerns have been
raised about the safety of broad-spectrum ﬂuoro-
quinolones following the discovery of serious
drug-related side effects with some agents in this
class. This has led to the withdrawal or restricted
clinical use of certain broad-spectrum ﬂuoroqui-
nolones, and a cautious approach to drug licensing
by the regulatory authorities.
To address potential concerns about the safety
and tolerability of gatiﬂoxacin, extensive post-
marketing surveillance studies have been carried
out following its approval in the USA for the
treatment of respiratory tract and other infections.
Results from a Phase IV post-marketing surveil-
lance trial carried out in 2000, involving over
15 000 patients treated with gatiﬂoxacin for res-
piratory tract infections, have shown gatiﬂoxacin
to be safe and well-tolerated when used in routine
clinical practice for the treatment of CAP and
other infections of the upper and lower respirat-
ory tract [32–34].
Results from the present Phase III study are in
accordance with these ﬁndings, with the inci-
dence and nature of adverse events observed with
gatiﬂoxacin being within the incidence range
reported elsewhere [35]. Gatiﬂoxacin had a safety
and tolerability proﬁle comparable to that of co-
amoxiclav, with adverse gastrointestinal events
being the most common treatment-related ad-
verse events in both groups. The study also
showed no evidence that gatiﬂoxacin induced
phototoxicity, musculoskeletal disorders or the
hepatic, cardiac and renal problems that have
been reported for some of the other broad-
spectrum ﬂuoroquinolones [36–39].
Discontinuations associated with adverse
events were similar in the two treatment groups,
reﬂecting the good tolerability of both agents.
Based on the current medical literature, the
discontinuation rates for gatiﬂoxacin were com-
parable to rates of < 4.1% reported for other
ﬂuoroquinolones [40]. Compared with co-amoxi-
clav, the long elimination half-life of gatiﬂoxacin
permits once-daily dosing, which provides a
convenient dosage schedule for patients with
CAP, and may offer advantages over the three-
times-daily dosing schedule for co-amoxiclav.
In conclusion, the results of this multicentre,
double-blind, randomised, double-dummy, par-
allel-group study have shown that a once-daily
dose of gatiﬂoxacin 400 mg administered for
5–10 days was a safe and effective treatment for
patients with CAP.
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